Clinical Utility of ALK Fusion Detection by Liquid Biopsy
Cell-free DNA NGS detects common and novel ALK fusions in the plasma of lung cancer patients.
Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled “Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions“. Read more